Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Inclusion Criteria:

- Patients who have successfully completed a qualifying study (D4300C00001,
D4300C00002, D4300C00003 or D4300C00004) with fostamatinib

- Patients who have participated in a qualifying study and who have been classified as
non-responders due to pre-defined lack of efficacy at Week 12 (D4300C00001,
D4300C00002, D4300C00003).

Exclusion Criteria:

- Premature withdrawal from the qualifying study (D4300C00001, D4300C00002, D4300C00003
and D4300C00004)

- Females who are pregnant or breast feeding

- Poorly controlled hypertension

- Significant liver function test abnormalities or physical symptoms of hepatotoxicity

- Significant infection

- Gastrointestinal intolerance

- Cancer